Di Padova C, Di Padova F, Buzzetti M, Tritapepe R
Scand J Gastroenterol. 1984 Sep;19(6):820-3.
The effects of the lipid-lowering agent 3-hydroxy-3-methylglutaric acid (HMGA) on serum lipids and on biliary lipid composition were evaluated in a double-blind, placebo-controlled study in normolipidemic volunteers. After 4 weeks of HMGA administration (1 g three times a day orally) serum total cholesterol showed a significant decrease with regard to both pretreatment values and corresponding values of controls. The bile lipid molar percentage composition and the cholesterol saturation index showed no modification after HMGA and did not differ from the values obtained in the placebo group. These findings indicate that HMGA exerts no adverse effects on bile lipid composition in humans, differing from other hypolipidemic drugs currently in clinical use, which increase the bile cholesterol saturation index.
在一项针对血脂正常志愿者的双盲、安慰剂对照研究中,评估了降脂药物3-羟基-3-甲基戊二酸(HMGA)对血脂和胆汁脂质成分的影响。在口服HMGA(每天3次,每次1 g)4周后,血清总胆固醇相对于治疗前值和对照组的相应值均显著降低。HMGA治疗后,胆汁脂质摩尔百分比组成和胆固醇饱和指数没有改变,且与安慰剂组获得的值没有差异。这些发现表明,HMGA对人体胆汁脂质成分没有不良影响,这与目前临床使用的其他降脂药物不同,后者会增加胆汁胆固醇饱和指数。